120 related articles for article (PubMed ID: 21278799)
1. Successful treatment with rituximab and donor lymphocyte infusions for fulminant EBV-associated lymphoproliferative disorder that developed 14 years after unrelated BMT.
Kawaguchi T; Tsukamoto S; Ohwada C; Takeuchi M; Muto T; Tanaka S; Sakai S; Takeda Y; Abe D; Sakaida E; Shimizu N; Yokote K; Iseki T; Imadome KI; Nakaseko C
Bone Marrow Transplant; 2011 Dec; 46(12):1583-5. PubMed ID: 21278799
[No Abstract] [Full Text] [Related]
2. Epstein-Barr virus-related lymphoproliferative disease complicating childhood acute lymphoblastic leukemia: no recurrence after unrelated donor bone marrow transplantation.
Pondarré C; Kebaili K; Dijoud F; Basset T; Philippe N; Bertrand Y
Bone Marrow Transplant; 2001 Jan; 27(1):93-5. PubMed ID: 11244444
[TBL] [Abstract][Full Text] [Related]
3. [Successful donor lymphocyte infusion for Epstein-Barr virus-associated lymphoproliferative disorder after allogeneic bone marrow transplantation from an HLA 1-locus-mismatched sibling donor in a patient with acute lymphocytic leukemia].
Yago K; Itoh M; Shimada H
Rinsho Ketsueki; 2001 Nov; 42(11):1105-10. PubMed ID: 11808079
[TBL] [Abstract][Full Text] [Related]
4. Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy.
Castagnola E; Dallorso S; Faraci M; Morreale G; Di Martino D; Cristina E; Scarso L; Lanino E
J Hematother Stem Cell Res; 2003 Feb; 12(1):9-10. PubMed ID: 12662431
[No Abstract] [Full Text] [Related]
5. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
Coppoletta S; Tedone E; Galano B; Soracco M; Raiola AM; Lamparelli T; Gualandi F; Bregante S; Ibatici A; di Grazia C; Dominietto A; Varaldo R; Bruno B; Frassoni F; Van Lint MT; Bacigalupo A
Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702
[TBL] [Abstract][Full Text] [Related]
6. Unmanipulated donor lymphocytes for EBV-related PTLD after T-cell depleted HLA-haploidentical transplantation.
De Pasquale MD; Mastronuzzi A; De Vito R; Cometa A; Inserra A; Russo C; De Ioris MA; Locatelli F
Pediatrics; 2012 Jan; 129(1):e189-94. PubMed ID: 22144701
[TBL] [Abstract][Full Text] [Related]
7. Donor lymphocyte transfusion for the treatment of Epstein-Barr virus-associated lymphoproliferative disorder of the brain.
Nagafuji K; Eto T; Hayashi S; Oshima K; Maeda Y; Gondo H; Inamura T; Niho Y
Bone Marrow Transplant; 1998 Jun; 21(11):1155-8. PubMed ID: 9645581
[TBL] [Abstract][Full Text] [Related]
8. Immune-cell treatment of Epstein--Barr-virus-associated lymphoproliferative disorders.
Swinnen LJ
Best Pract Res Clin Haematol; 2006; 19(4):839-47. PubMed ID: 16997187
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
10. Rapidly progressive Epstein-Barr virus-associated lymphoproliferative disorder unpredictable by weekly viral load monitoring.
Wakabayashi S; Ohashi K; Hanajiri R; Kobayashi T; Yamashita T; Akiyama H; Sakamaki H
Intern Med; 2010; 49(10):931-5. PubMed ID: 20467179
[TBL] [Abstract][Full Text] [Related]
11. Unsuccessful CTL transfusion in a case of post-BMT Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD).
Imashuku S; Goto T; Matsumura T; Naya M; Yamori M; Hojo M; Hibi S; Todo S
Bone Marrow Transplant; 1997 Aug; 20(4):337-40. PubMed ID: 9285550
[TBL] [Abstract][Full Text] [Related]
12. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease.
Okamura T; Kishimoto T; Inoue M; Honda M; Yamashita N; Wakiguchi H; Yagita M; Hosoi G; Sako M; Yasui M; Yagi K; Kawa K
Bone Marrow Transplant; 2003 Jan; 31(2):105-11. PubMed ID: 12621491
[TBL] [Abstract][Full Text] [Related]
13. Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?
Savani BN; Pohlmann PR; Jagasia M; Chinratanalab W; Kassim A; Engelhardt B; Greer J; Schuening F; Goodman S
Blood; 2009 Jun; 113(24):6263-4. PubMed ID: 19520823
[No Abstract] [Full Text] [Related]
14. Epstein-Barr virus-associated leukemic lymphoma after allogeneic stem cell transplantation.
Takamatsu H; Araki R; Nishimura R; Yachie A; Espinoza JL; Okumura H; Yoshida T; Kuzushima K; Nakao S
J Clin Virol; 2016 Jul; 80():82-6. PubMed ID: 27218416
[TBL] [Abstract][Full Text] [Related]
15. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
Styczynski J; Einsele H; Gil L; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disorder simultaneously affecting both B and T cells after allogeneic bone marrow transplantation.
Chuhjo T; Yachie A; Kanegane H; Kimura H; Shiobara S; Nakao S
Am J Hematol; 2003 Apr; 72(4):255-8. PubMed ID: 12666136
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
Meijer E; Cornelissen JJ
Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation.
Chiang KY; Hazlett LJ; Godder KT; Abhyankar SH; Christiansen NP; van Rhee F; Lee CG; Bridges K; Parrish RS; Henslee-Downey PJ
Bone Marrow Transplant; 2001 Dec; 28(12):1117-23. PubMed ID: 11803352
[TBL] [Abstract][Full Text] [Related]
19. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation.
McGuirk JP; Seropian S; Howe G; Smith B; Stoddart L; Cooper DL
Bone Marrow Transplant; 1999 Dec; 24(11):1253-8. PubMed ID: 10642818
[TBL] [Abstract][Full Text] [Related]
20. [Epstein-Barr virus-associated post-transplant lymphoproliferative disorder diagnosed by the episode of intestinal perforation following allogeneic hematopoietic stem cell transplantation].
Aimoto M; Yamane T; Inoue A; Momose D; Moriguchi-Aimoto R; Wada-Inoue E; Okamoto S; Koh H; Nakane T; Takeoka Y; Akahori-Nakamae M; Nishiki-Kosaka S; Terada Y; Nakamae H; Koh KR; Nakao T; Ohsawa M; Hino M
Rinsho Ketsueki; 2010 Dec; 51(12):1775-80. PubMed ID: 21258188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
